Pacira | PCRX - Net Income


Pacira reported $2.92M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Astellas Pharma JPY 43.52B 56.86B Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cara Therapeutics USD -5.53M 621K Sep/2025
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
J&J USD 5.24B 119M Mar/2026
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 2.92M 1.28M Mar/2026
Perrigo USD -398.6M 1.02B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024
Zoetis USD 601M 2M Mar/2026